4.5 Article

Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling

Journal

MOLECULAR IMMUNOLOGY
Volume 45, Issue 8, Pages 2277-2287

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2007.11.018

Keywords

mitochondrial anti-viral signaling protein; caspase activation and recruitment domain; splicing variant; retinoic acid-induced gene I

Funding

  1. NCI NIH HHS [R01 CA098160-05] Funding Source: Medline
  2. NIAID NIH HHS [K22 AI051534-02] Funding Source: Medline

Ask authors/readers for more resources

The mitochondrial anti-viral signaling protein (MAVS), also known as CARDIF, IPS-1, KIAA1271 and VISA, is a mitochondria associated protein that regulates type I interferon production through coordinated activation of NF-kappa B and IRF3. The N-terminal CARD domain of MAVS interacts with RIGI helicase of upcapped RNA detection and the putative TRAF2 and TRAF6 binding motifs modulate protein interaction for NF-kappa B activation. MAVS is encoded by a single gene composed of 6 exons but is generally detected as multiple protein bands after separation by SDS-PAGE. In an effort to identify MAVS variants with diverse biological functions, we isolated three splicing variants and named them MAVS I a (exon 2 deletion), 1b (exon 3 deletion) and I c (exon 6 deletion), respectively. MAVS I a and 1b, due to a frame shift by exon deletion, encode 131 and 124 aa residues, respectively. Except the first 39 aa residues encoded by exon 1, MAVS I a does not share sequence homology with known proteins, it instead contains a putative TRAF2-binding motif and interacts with TRAF2 and RIP1. MAVS 1b shares the first 97 residues with wt MAVS and 27 aa residues of unknown protein. Unlike MAVS that activates both NF-kappa B and IRF3 pathways, expression of MAVS 1b selectively activates an IFN beta but not an IL8 promoter. MAVS 1b interacts with RIP1 and FADD and exhibits anti-viral activity against VSV infection. This study uncovers MAVS splicing variants of diverse biological function. (C) 2007 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available